Clinical Trial Update: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. [Phase 3]

View source ↗

Summary

Phase 3 study evaluating criteria for re-treatment with ranibizumab in patients with visual impairment from choroidal neovascularization secondary to pathologic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization Secondary to Pathologic Myopia

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Status: COMPLETED | Results posted: 2019-02-18